Deactivating Indoor Allergens Associated with Childhood Asthma

描述(由申请人提供)：Carbonix LLC就其新工艺提出了一项第一阶段研究计划，以减少与过敏和哮喘发作有关的室内过敏蛋白。例如，常见的过敏性蛋白是由家用尘螨和猫产生的。据推测，CarboNix过程将使蛋白质失活和/或溶解，最大限度地减少暴露，并减轻与室内过敏原密切相关的过敏发作和哮喘发作。同时，这一过程将杀死粉尘，这是室内有效过敏原的主要来源。初步研究表明，该方法可以去除大约70%的主要尘螨过敏原和80%以上的猫过敏原。 室内过敏原是人们生活、学习和工作的室内环境退化的重要原因。超过5000万美国人患有过敏症，每年有380万人因过敏而失去工作或上学。室内过敏原也与哮喘的触发有关，哮喘是一种潜在的致命疾病，影响着大约3250万美国人，每年造成超过190亿美元的损失。CarboNix的长期目标是为室内过敏原和哮喘是严重健康问题的个人和机构提供过敏缓解服务。第一阶段SBIR项目的完成将证明进一步将这一过程发展为减敏业务的可行性，并将为后续第二阶段的进一步研究、设计和商业化活动提供科学和工程基础。 与公众健康相关：这一SBIR第一阶段项目旨在开发一种减少或消除室内过敏原的过程，特别是由尘螨和猫产生的过敏原。超过5000万美国人患有过敏症，每年有380万人因过敏而失去工作或上学。室内过敏原也与哮喘的触发有关，哮喘是一种潜在的致命疾病，影响着大约3250万美国人，每年造成超过190亿美元的损失。

DESCRIPTION (provided by applicant): Carbonix LLC proposes a Phase I research program on its novel process that abates indoor allergenic proteins that are implicated in allergies and asthma attacks. Common allergenic proteins are produced, for example, by household dust mites and cats. It is hypothesized that the CarboNix process will deactivate and/or dissolve the proteins, minimizing exposure and mitigating allergy attacks as well as asthma attacks, which are strongly associated with indoor allergens. Simultaneously, the process will kill dust mites, a major source of potent indoor allergens. Preliminary studies have demonstrated that the process can remove approximately 70% of a major dust mite allergen and greater than 80% of cat allergen. Indoor allergens contribute significantly to the degradation of indoor environments where people live, learn, and work. More than 50 million Americans suffer from allergies, which are responsible for 3.8 million lost work or school days per year. Indoor allergens are also implicated in the triggering of asthma, a potentially fatal condition that affects about 32.5 million Americans and costs over $19 billion annually. The long-term goal of CarboNix is to provide allergy abatement services to individuals and institutions where indoor allergens and asthma are severe health issues. Completion of this Phase I SBIR project will demonstrate the feasibility of further developing this process into an allergy abatement business, and will provide the scientific and engineering basis for further research, design, and commercialization activities in a subsequent Phase II. PUBLIC HEALTH RELEVANCE: This Phase I SBIR project is aimed at developing a process that will reduce or eliminate indoor allergens, specifically those produced by dust mites and cats. More than 50 million Americans suffer from allergies, which are responsible for 3.8 million lost work or school days per year. Indoor allergens are also implicated in the triggering of asthma, a potentially fatal condition that affects about 32.5 million Americans and costs over $19 billion annually.